Demographics and baseline characteristics of patients included in the OPTIPRIM2-ANRS 169 trial
| Patient characteristics . | Dolutegravir group (n = 51) . | Darunavir/cobicistat group (n = 50) . | All (N = 101) . |
|---|---|---|---|
| Age (years), median (IQR) | 35 (29–45) | 38 (29–51) | 36 (28–49) |
| Men, n (%) | 49 (96) | 45 (90) | 94 (93) |
| MSM, n (%) | 38 (75) | 32 (64) | 70 (69) |
| Weight (kg), median (IQR) | 68 (63–76) | 70 (63–78) | 69 (63–78) |
| Geographical origin, n (%) | |||
| Europe | 39 (76) | 41 (82) | 80 (79) |
| Sub-Saharan Africa | 3 (6) | 4 (8) | 7 (7) |
| Other | 9 (18) | 5 (10) | 14 (14) |
| Symptomatic infection, n (%) | 45 (88) | 45 (90) | 90 (89) |
| HIV-1 RNA level (log10 copies/mL)a, median (IQR) | 5.52 (4.88–6.30) | 6.07 (5.15–6.97) | 5.77 (5.04–6.57) |
| HIV-1 DNA level (log10 copies/106 PBMCs), median (IQR) | 3.77 (3.42–4.06) | 3.96 (3.62–4.26) | 3.87 (3.52–4.15) |
| CD4+ T cell count (cells/mm3), median (IQR) | 442 (343–587) | 434 (305–643) | 437 (333–602) |
| CD8+ T cell count (cells/mm3), median (IQR) | 980 (556–1280) | 840 (529–1294) | 878 (548–1287) |
| CD4+/CD8+ ratio, median (IQR) | 0.49 (0.29–0.70) | 0.52 (0.35–0.74) | 0.51 (0.32–0.73) |
| Subtype, n (%) | |||
| B | 25/49 (51) | 22/50 (44) | 47/99 (47) |
| CRF02 | 7/49 (14) | 16/50 (32) | 23/99 (23) |
| Other | 17/49 (35) | 12/50 (24) | 29/99 (29) |
| Genotypic resistance to drug regimen, n | 1 (emtricitabine) | 1 (tenofovir) | |
| Time between diagnosis and treatment initiation (days), median (IQR) | 1 (0–4) | 2 (1–3) | 2 (1–3) |
| Patient characteristics . | Dolutegravir group (n = 51) . | Darunavir/cobicistat group (n = 50) . | All (N = 101) . |
|---|---|---|---|
| Age (years), median (IQR) | 35 (29–45) | 38 (29–51) | 36 (28–49) |
| Men, n (%) | 49 (96) | 45 (90) | 94 (93) |
| MSM, n (%) | 38 (75) | 32 (64) | 70 (69) |
| Weight (kg), median (IQR) | 68 (63–76) | 70 (63–78) | 69 (63–78) |
| Geographical origin, n (%) | |||
| Europe | 39 (76) | 41 (82) | 80 (79) |
| Sub-Saharan Africa | 3 (6) | 4 (8) | 7 (7) |
| Other | 9 (18) | 5 (10) | 14 (14) |
| Symptomatic infection, n (%) | 45 (88) | 45 (90) | 90 (89) |
| HIV-1 RNA level (log10 copies/mL)a, median (IQR) | 5.52 (4.88–6.30) | 6.07 (5.15–6.97) | 5.77 (5.04–6.57) |
| HIV-1 DNA level (log10 copies/106 PBMCs), median (IQR) | 3.77 (3.42–4.06) | 3.96 (3.62–4.26) | 3.87 (3.52–4.15) |
| CD4+ T cell count (cells/mm3), median (IQR) | 442 (343–587) | 434 (305–643) | 437 (333–602) |
| CD8+ T cell count (cells/mm3), median (IQR) | 980 (556–1280) | 840 (529–1294) | 878 (548–1287) |
| CD4+/CD8+ ratio, median (IQR) | 0.49 (0.29–0.70) | 0.52 (0.35–0.74) | 0.51 (0.32–0.73) |
| Subtype, n (%) | |||
| B | 25/49 (51) | 22/50 (44) | 47/99 (47) |
| CRF02 | 7/49 (14) | 16/50 (32) | 23/99 (23) |
| Other | 17/49 (35) | 12/50 (24) | 29/99 (29) |
| Genotypic resistance to drug regimen, n | 1 (emtricitabine) | 1 (tenofovir) | |
| Time between diagnosis and treatment initiation (days), median (IQR) | 1 (0–4) | 2 (1–3) | 2 (1–3) |
The HIV-1 RNA level was missing for one participant due to a non-amplifiable HIV-1 N subtype. Immunological data were missing for one patient because no sample was available.
Demographics and baseline characteristics of patients included in the OPTIPRIM2-ANRS 169 trial
| Patient characteristics . | Dolutegravir group (n = 51) . | Darunavir/cobicistat group (n = 50) . | All (N = 101) . |
|---|---|---|---|
| Age (years), median (IQR) | 35 (29–45) | 38 (29–51) | 36 (28–49) |
| Men, n (%) | 49 (96) | 45 (90) | 94 (93) |
| MSM, n (%) | 38 (75) | 32 (64) | 70 (69) |
| Weight (kg), median (IQR) | 68 (63–76) | 70 (63–78) | 69 (63–78) |
| Geographical origin, n (%) | |||
| Europe | 39 (76) | 41 (82) | 80 (79) |
| Sub-Saharan Africa | 3 (6) | 4 (8) | 7 (7) |
| Other | 9 (18) | 5 (10) | 14 (14) |
| Symptomatic infection, n (%) | 45 (88) | 45 (90) | 90 (89) |
| HIV-1 RNA level (log10 copies/mL)a, median (IQR) | 5.52 (4.88–6.30) | 6.07 (5.15–6.97) | 5.77 (5.04–6.57) |
| HIV-1 DNA level (log10 copies/106 PBMCs), median (IQR) | 3.77 (3.42–4.06) | 3.96 (3.62–4.26) | 3.87 (3.52–4.15) |
| CD4+ T cell count (cells/mm3), median (IQR) | 442 (343–587) | 434 (305–643) | 437 (333–602) |
| CD8+ T cell count (cells/mm3), median (IQR) | 980 (556–1280) | 840 (529–1294) | 878 (548–1287) |
| CD4+/CD8+ ratio, median (IQR) | 0.49 (0.29–0.70) | 0.52 (0.35–0.74) | 0.51 (0.32–0.73) |
| Subtype, n (%) | |||
| B | 25/49 (51) | 22/50 (44) | 47/99 (47) |
| CRF02 | 7/49 (14) | 16/50 (32) | 23/99 (23) |
| Other | 17/49 (35) | 12/50 (24) | 29/99 (29) |
| Genotypic resistance to drug regimen, n | 1 (emtricitabine) | 1 (tenofovir) | |
| Time between diagnosis and treatment initiation (days), median (IQR) | 1 (0–4) | 2 (1–3) | 2 (1–3) |
| Patient characteristics . | Dolutegravir group (n = 51) . | Darunavir/cobicistat group (n = 50) . | All (N = 101) . |
|---|---|---|---|
| Age (years), median (IQR) | 35 (29–45) | 38 (29–51) | 36 (28–49) |
| Men, n (%) | 49 (96) | 45 (90) | 94 (93) |
| MSM, n (%) | 38 (75) | 32 (64) | 70 (69) |
| Weight (kg), median (IQR) | 68 (63–76) | 70 (63–78) | 69 (63–78) |
| Geographical origin, n (%) | |||
| Europe | 39 (76) | 41 (82) | 80 (79) |
| Sub-Saharan Africa | 3 (6) | 4 (8) | 7 (7) |
| Other | 9 (18) | 5 (10) | 14 (14) |
| Symptomatic infection, n (%) | 45 (88) | 45 (90) | 90 (89) |
| HIV-1 RNA level (log10 copies/mL)a, median (IQR) | 5.52 (4.88–6.30) | 6.07 (5.15–6.97) | 5.77 (5.04–6.57) |
| HIV-1 DNA level (log10 copies/106 PBMCs), median (IQR) | 3.77 (3.42–4.06) | 3.96 (3.62–4.26) | 3.87 (3.52–4.15) |
| CD4+ T cell count (cells/mm3), median (IQR) | 442 (343–587) | 434 (305–643) | 437 (333–602) |
| CD8+ T cell count (cells/mm3), median (IQR) | 980 (556–1280) | 840 (529–1294) | 878 (548–1287) |
| CD4+/CD8+ ratio, median (IQR) | 0.49 (0.29–0.70) | 0.52 (0.35–0.74) | 0.51 (0.32–0.73) |
| Subtype, n (%) | |||
| B | 25/49 (51) | 22/50 (44) | 47/99 (47) |
| CRF02 | 7/49 (14) | 16/50 (32) | 23/99 (23) |
| Other | 17/49 (35) | 12/50 (24) | 29/99 (29) |
| Genotypic resistance to drug regimen, n | 1 (emtricitabine) | 1 (tenofovir) | |
| Time between diagnosis and treatment initiation (days), median (IQR) | 1 (0–4) | 2 (1–3) | 2 (1–3) |
The HIV-1 RNA level was missing for one participant due to a non-amplifiable HIV-1 N subtype. Immunological data were missing for one patient because no sample was available.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
